EOSINOPHILIC IMMUNE DYSFUNCTION
ACROSS INFLAMMATORY DISEASES

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)

Eosinophilic
asthma (EA)

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Eosinophilic
esophagitis (EoE)

Eosinophilic granulomatosis with polyangiitis (EGPA)

Hyper eosinophilic
syndrome (HES)

WHAT IS EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)?

Eosinophilic granulomatosis with polyangiitis (EGPA), previously called Churg-Strauss syndrome, is a rare autoimmune disease characterized by eosinophil-rich granulomatous inflammation and small- and medium-sized blood vessel vasculitis.1


Symptoms of EGPA2,3

Symptoms of Eosinophilic Granulomatosis with Polyangiitis
Symptoms of Eosinophilic Granulomatosis with Polyangiitis

 

The prevalence of EGPA is 10.7 per million to 17.8 per million worldwide.*1

*Depending on geographic regions and applied criteria.

 

THE ROLE OF EOSINOPHILIC IMMUNE DYSFUNCTION IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Although the etiology of EGPA is not completely understood, eosinophils
have a role in disease pathogenesis.1,4

 

Eosinophil infiltration of tissues is at least partly responsible for the
end-organ damage associated with EGPA.1

 

Role of Eosinophilic Immune Dysfunction in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Role of Eosinophilic Immune Dysfunction in Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Adapted from Furuta S. Allergol Int. 2019.1

APC=antigen-presenting cell.
*These are genes of which variations and mutations can contribute to the predisposition to eosinophilic inflammation.

 

CLINICAL CONSEQUENCES OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

Overall mortality rate for patients with EGPA is 20%-25% over 5 years to 10 years.5

 

Over the years, prognosis of patients with EGPA has improved, especially with respect to mortality, owing
to advancements in diagnostic criteria and appropriate treatments2,6

 

When patients have ≥1 of the following factors there is an increased mortality risk6,7

Clinical Consequences of Eosinophilic Granulomatosis with Polyangiitis
Clinical Consequences of Eosinophilic Granulomatosis with Polyangiitis

ASTRAZENECA IS COMMITTED TO UNCOVERING THE ROLE OF EOSINOPHILIC IMMUNE DYSFUNCTION IN EOSIONPHILIC GRANULOMATOSIS WITH POLYANGIITIS.